Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marina Bacac

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
Cell|May 6, 2017
An Immune Atlas of Clear Cell Renal Cell CarcinomaStéphane Chevrier, Jacob Harrison Levine, Vito Riccardo Tomaso Zanotelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2018
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic MalignanciesMarina Bacac, Sara Colombetti, Sylvia Herter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2023
Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific AntibodiesGabrielle Leclercq-Cohen, Nathalie Steinhoff, Llucia Albertí Servera, et al.
Molecular Cancer Therapeutics|July 23, 2013
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft modelsSylvia Herter, Frank Herting, Olaf Mundigl, et al.
Med (New York, N.Y.)|April 9, 2024
Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanomaRamona Schlenker, Petra C Schwalie, Steffen Dettling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2021
Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF InhibitorJürgen Wichmann, Caroline Rynn, Thomas Friess, et al.
Journal for Immunotherapy of Cancer|July 4, 2020
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancerMarta Trüb, Franziska Uhlenbrock, Christina Claus, et al.
Blood|August 1, 2025
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphomaJohannes Sam, Gabrielle Leclercq-Cohen, Samuel Gebhardt, et al.
Cancer Immunology Research|November 16, 2021
BET Inhibition Enhances TNF-Mediated Antitumor ImmunityLisa C Wellinger, Simon J Hogg, Dane M Newman, et al.
Cancer Research Communications|June 12, 2026
Tobemstomig, a novel bispecific antibody, preferentially blocks PD-1 and LAG-3 on CD8 TILs to expand stem-like T-cells for sustained tumor controlPatrick A A Weber, Mario Perro, Valeria G Nicolini, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Cell|May 6, 2017
An Immune Atlas of Clear Cell Renal Cell CarcinomaStéphane Chevrier, Jacob Harrison Levine, Vito Riccardo Tomaso Zanotelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2018
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic MalignanciesMarina Bacac, Sara Colombetti, Sylvia Herter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2023
Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific AntibodiesGabrielle Leclercq-Cohen, Nathalie Steinhoff, Llucia Albertí Servera, et al.
Molecular Cancer Therapeutics|July 23, 2013
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft modelsSylvia Herter, Frank Herting, Olaf Mundigl, et al.
Med (New York, N.Y.)|April 9, 2024
Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanomaRamona Schlenker, Petra C Schwalie, Steffen Dettling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2021
Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF InhibitorJürgen Wichmann, Caroline Rynn, Thomas Friess, et al.
Journal for Immunotherapy of Cancer|July 4, 2020
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancerMarta Trüb, Franziska Uhlenbrock, Christina Claus, et al.
Blood|August 1, 2025
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphomaJohannes Sam, Gabrielle Leclercq-Cohen, Samuel Gebhardt, et al.
Cancer Immunology Research|November 16, 2021
BET Inhibition Enhances TNF-Mediated Antitumor ImmunityLisa C Wellinger, Simon J Hogg, Dane M Newman, et al.
Cancer Research Communications|June 12, 2026
Tobemstomig, a novel bispecific antibody, preferentially blocks PD-1 and LAG-3 on CD8 TILs to expand stem-like T-cells for sustained tumor controlPatrick A A Weber, Mario Perro, Valeria G Nicolini, et al.
Pageof 8